Definium Therapeutics Inc (DFTX)

Definium Therapeutics Announces New Employee Inducement Grants

Definium Therapeutics, Inc. (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year

A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year Canada...

Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new...

Form 144 - Report of proposed sale of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Form 424B5 - Prospectus [Rule 424(b)(5)]

Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new...

Form 424B5 - Prospectus [Rule 424(b)(5)]

Definium Therapeutics, Inc. Announces Proposed Public Offering

Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities